Document Detail


GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance.
MedLine Citation:
PMID:  22414725     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The overexpression of ATP binding cassette (ABC) transporters often leads to the development of multidrug resistance (MDR) and results in a suboptimal response to chemotherapy. Previously, we reported that lapatinib (GW572016), a human epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinase inhibitor (TKI), significantly reverses MDR in cancer cells by blocking the efflux function of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2). In the present study, we conducted in vitro experiments to evaluate if GW583340 and GW2974, structural analogues of lapatinib, could reverse ABCB1- and ABCG2-mediated MDR. Our results showed that GW583340 and GW2974 significantly sensitized ABCB1 and ABCG2 overexpressing MDR cells to their anticancer substrates. GW583340 and GW2974 significantly increased the intracellular accumulation of [(3)H]-paclitaxel in ABCB1 overexpressing cells and [(3)H]-mitoxantrone in ABCG2 overexpressing cells respectively. In addition, GW583340 and GW2974 significantly inhibited ABCG2-mediated transport of methotrexate in ABCG2 overexpressing membrane vesicles. There was no significant change in the expression levels of ABCB1 and ABCG2 in the cell lines exposed to 5μM of either GW583340 or GW2974 for 3 days. In addition, a docking model predicted the binding conformation of GW583340 and GW2974 to be within the transmembrane region of homology modeled human ABCB1 and ABCG2. We conclude that GW583340 and GW2974, at clinically achievable plasma concentrations, reverse ABCB1- and ABCG2-mediated MDR by blocking the drug efflux function of these transporters. These findings may be useful in developing combination therapy for cancer treatment with EGFR TKIs.
Authors:
Kamlesh Sodani; Amit K Tiwari; Satyakam Singh; Atish Patel; Zhi-Jie Xiao; Jun-Jiang Chen; Yue-Li Sun; Tanaji T Talele; Zhe-Sheng Chen
Related Documents :
22870135 - Isolation and characterization of erlotinib-resistant human non-small cell lung cancer ...
18614005 - Rab5 and rac team up in cell motility.
20696765 - Semaphorin 5a and plexin-b3 inhibit human glioma cell motility through rhogdialpha-medi...
17997595 - Stochastic noise and synchronisation during dictyostelium aggregation make camp oscilla...
23096415 - The postnatal human filum terminale is a source of autologous multipotent neurospheres ...
12527255 - Chemically patterned, metal-oxide-based surfaces produced by photolithographic techniqu...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-03-07
Journal Detail:
Title:  Biochemical pharmacology     Volume:  83     ISSN:  1873-2968     ISO Abbreviation:  Biochem. Pharmacol.     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-04-23     Completed Date:  2012-06-22     Revised Date:  2013-06-26    
Medline Journal Info:
Nlm Unique ID:  0101032     Medline TA:  Biochem Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1613-22     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Affiliation:
Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John's University, Queens, NY 11439, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
ATP-Binding Cassette Transporters / physiology*
Blotting, Western
Cell Line, Tumor
Drug Resistance, Neoplasm*
Humans
Models, Molecular
Neoplasm Proteins / physiology*
Quinazolines / pharmacology*
Receptor, Epidermal Growth Factor / antagonists & inhibitors*
Receptor, erbB-2 / antagonists & inhibitors*
Sulfones / pharmacology*
Grant Support
ID/Acronym/Agency:
1R15CA143701/CA/NCI NIH HHS; R15 CA143701/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/ABCG2 protein, human; 0/GW 583340; 0/GW2974; 0/Neoplasm Proteins; 0/Quinazolines; 0/Sulfones; EC 2.7.10.1/Receptor, Epidermal Growth Factor; EC 2.7.10.1/Receptor, erbB-2
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Knowledge of Risk Factors and Stroke Symptoms among Nonstroke Patients.
Next Document:  Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation.